To understand why this matters, it helps to start with the biology of oxidative stress. The liver is a metabolic furnace: its mitochondria, its NADPH oxidases, its inducible nitric oxide synthase, and its cytochrome P450 enzymes all generate reactive oxygen and nitrogen species as byproducts of detoxification and metabolism. Under healthy conditions, an elaborate antioxidant arsenal, including reduced glutathione, thioredoxin, superoxide dismutase, catalase, and peroxiredoxins, keeps these oxidants in check. The expression of much of this arsenal is coordinated by Nrf2, a transcription factor discovered in 1994. In resting cells, Nrf2 is continuously captured by its repressor Keap1 and shuttled to the proteasome for destruction. When oxidative or electrophilic stress modifies critical cysteine residues on Keap1, Nrf2 escapes degradation, translocates to the nucleus, and binds antioxidant response elements to switch on genes such as NQO1, heme oxygenase-1, and the glutathione-synthesis machinery. When this system fails, persistent oxidative damage drives apoptosis, necrosis, and inflammation, fueling diseases from cardiovascular pathology to cancer.

The review’s central insight is that Nrf2’s behavior is strikingly context-dependent across liver diseases. In alcoholic liver disease, chronic ethanol consumption induces CYP2E1, an enzyme that generates torrents of reactive oxygen species while metabolizing alcohol, creating a vicious cycle of oxidative injury. Upstream regulators such as the deacetylase SIRT6, the endoplasmic reticulum chaperone ERdj5, and the autophagy protein SNX10 all bolster Nrf2 signaling to counter this assault. In metabolic dysfunction-associated fatty liver disease, high-fat diets suppress autophagosome biogenesis through mTOR signaling, which stabilizes Keap1 and degrades Nrf2, leaving hepatocytes vulnerable to ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation. Yet Nrf2 activation in this setting is double-edged: it also upregulates lipid transporters such as CD36 and the very-low-density lipoprotein receptor, and promotes the lipogenic program of PPARγ, meaning that boosting Nrf2 can simultaneously protect against oxidative damage and worsen fat accumulation.

In acute drug-induced liver injury, exemplified by acetaminophen overdose, the stakes are starker. A small fraction of acetaminophen is converted by CYP2E1 into NAPQI, a highly reactive metabolite that exhausts glutathione stores and covalently damages mitochondrial proteins. Nrf2-knockout mice are far more susceptible to this injury than wild-type animals because they cannot replenish glutathione efficiently, and a cascade of regulators, from the deubiquitinase USP25 to the autophagy receptor p62 and the transcription factor TFEB, modulates how robustly Nrf2 responds. Despite decades of research, N-acetyl cysteine remains the only approved therapy for acetaminophen overdose, with a narrow therapeutic window and notable side effects, which is precisely why the review’s microbiome-focused angle has attracted attention. In hepatocellular carcinoma, the picture inverts entirely: transient Nrf2 activation suppresses tumor initiation, but constitutive activation in established tumors, often driven by p62 accumulation, TSPO, or TRIM25, promotes progression, immune escape, pseudohypoxia, and resistance to ferroptosis-inducing therapies such as sorafenib.

The heart of the review is its argument that the gut microbiota acts as an upstream driver of all of this hepatic Nrf2 activity. Because the liver is the first organ to receive portal blood, its Nrf2 signaling is perpetually bathed in microbial biochemical signals. Specific probiotic strains have now been shown to exploit this route. Lacticaseibacillus rhamnosus GG, one of the best-characterized probiotics, protects against alcoholic and drug-induced liver injury, and a landmark integrated metabolomics and transcriptomics study identified its metabolite 5-methoxyindoleacetic acid, a tryptophan derivative, as a direct activator of hepatic Nrf2 that induces antioxidant genes including NQO1, HMOX1, and GCLC. Intriguingly, the same metabolite has been linked to longevity in centenarian cohort studies. Bifidobacterium longum strains produce sedanolide and indole-3-lactic acid, both of which activate Nrf2 and its target genes, while Lachnospiraceae bacteria, whose loss is a hallmark of alcoholic liver disease, generate butyrate and N-acetyl-glutamic acid that engage Nrf2 and inhibit ferroptosis. Akkermansia muciniphila, depleted in patients with alcoholic liver disease, contributes short-chain fatty acids that maintain hepatic redox homeostasis.

These microbial metabolites fall into chemically distinct classes with convergent endpoints. Short-chain fatty acids such as acetate, propionate, and butyrate, fermented from dietary fiber, act through pathways including AMPK-ULK1-p62 signaling to induce both mitophagy and Nrf2-driven antioxidant transcription; butyrate has even been proposed as a synergistic partner for N-acetyl cysteine in acetaminophen poisoning. Tryptophan metabolites, particularly indole derivatives, operate largely through the aryl hydrocarbon receptor, which is coordinately regulated with Nrf2 in what the field calls the AhR-Nrf2 gene battery, protecting both the intestinal barrier and the liver itself. Urolithins, produced by gut bacteria from the ellagitannins abundant in pomegranates, activate Nrf2/ARE signaling and promote mitophagy, with urolithin A outperforming N-acetyl cysteine in preclinical head-to-head comparisons of dosing and therapeutic window. Bacterial exopolysaccharides scavenge free radicals directly while activating Keap1/Nrf2 pathways. Not all microbial chemistry is benign, however: trimethylamine N-oxide, derived from dietary choline and carnitine, suppresses Nrf2-mediated antioxidant responses and induces hepatic endoplasmic reticulum stress, underscoring that the microbiota’s influence is genuinely dual-edged.

Perhaps the most technically sophisticated section of the review concerns microbial enzymes, the molecular interface that converts inert dietary precursors into Nrf2 modulators. Beta-galactosidase from Lactobacillus vaginalis liberates the isoflavone daidzein from the diet, which then activates an AKT-GSK3β-Nrf2 pathway and inhibits ferroptosis in acetaminophen injury. A related enzyme from Rikenella microfusus promotes absorption of the isoflavone biochanin-A, boosting glutathione synthesis. Formate C-acetyltransferase in Bifidobacterium generates indole-3-carboxylic acid, which inactivates CYP2E1 itself, while phenyllactate dehydrogenase in Limosilactobacillus reuteri produces indole-3-lactic acid, which dampens NLRP3 inflammasome activation in macrophages. The authors frame this as a new research paradigm, moving microbiome science beyond simple probiotic-versus-pathogen attribution toward a systematic chain of microbiota, microbial enzyme, metabolite, and target protein, a logic that has recently extended to gut fungi and bacteriophages as well.

On the therapeutic front, the review surveys four intervention strategies. Prebiotics, particularly plant polysaccharides and polyphenols, selectively enrich beneficial bacteria and indirectly upregulate hepatic Nrf2, HO-1, and GCLC, with randomized trial evidence already supporting oligofructose in fatty liver disease. Fecal microbiota transplantation remodels the entire ecosystem, and animal studies show that donors pretreated with polyphenols or other compounds transfer SCFA-rich communities that promote hepatic Nrf2 nuclear translocation; clinical trials have demonstrated improved intestinal permeability in fatty liver disease and acceptable safety in alcohol-associated liver failure, though bacteraemia and other adverse events have been reported. Dietary interventions rich in fiber and polyphenols feed the Nrf2-activating metabolite pipeline, whereas Western-style diets promote dysbiosis and harmful metabolites. Finally, combining microbiome modulation with direct Nrf2 activators such as sulforaphane, which broccoli seed extract delivers alongside a bloom of Akkermansia and Lactobacillus, may produce synergistic hepatoprotection.

Substantial obstacles remain before the gut-microbiota-Nrf2 axis reaches the clinic. Interindividual variability is profound: fiber supplementation reliably raises short-chain fatty acid production only in Prevotella-abundant individuals, roughly forty percent of people lack the Gordonibacter species needed to convert ellagitannins into urolithins, and dysbiotic guts shunt tryptophan toward proinflammatory kynurenines instead of protective indoles. Nrf2’s dual role poses a clinical dilemma, since sustained activation could promote tumor progression in patients with premalignant lesions, and timing matters, as Nrf2 activation works best before injury onset. There are no standardized clinical biomarkers for hepatic Nrf2 activity, animal models translate poorly, and regulatory frameworks for live biotherapeutic products are still maturing. The authors also caution that the relationship is a bidirectional closed loop, with Nrf2 activation reshaping bile acid profiles that in turn select for Nrf2-activating bacteria, a self-regulating circuit that remains largely a conceptual model. Even so, the framework offers something the field has lacked: a mechanistic explanation for why plant-rich diets, probiotics, and microbial metabolites protect the liver, and a roadmap for engineering that protection deliberately rather than leaving it to chance.

Subject of Research: Microbial regulation of the Nrf2 antioxidant signaling pathway in oxidative liver injury via the gut-liver axis

Article Title: Targeting Nrf2 in oxidative liver injury: Expanding the role of gut microbiota and metabolites

Article References: Luo, Y., Jiang, Y., & Zhou, T. (2026). Targeting Nrf2 in oxidative liver injury: Expanding the role of gut microbiota and metabolites. Journal of Advanced Research. https://doi.org/10.1016/j.jare.2026.09.006

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.09.006

Keywords: Nrf2, Keap1, gut-liver axis, gut microbiota, oxidative stress, liver injury, short-chain fatty acids, tryptophan metabolites, urolithins, ferroptosis, alcoholic liver disease, drug-induced liver injury